SCHEMBL14902608

SCHEMBL14902608

Cc1ccc(-c2cc3ncccc3c(N3CCOCC3)n2)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.47
ALOX15 P16050 2/20 0.47
METAP1 P53582 2/20 0.47
AHR P35869 1/20 0.47
SYK P43405 2/20 0.47
ALDH1A1 P00352 6/20 0.47
LMNA P02545 2/20 0.47
KDM4E B2RXH2 2/20 0.47
GAA P10253 2/20 0.47
NPC1 O15118 1/20 0.47
HCRTR1 O43613 1/20 0.47
MAPT P10636 1/20 0.47
RAB9A P51151 1/20 0.47
PIK3CA P42336 3/20 0.46
PIK3C2A O00443 1/20 0.46
PIK3C2B O00750 1/20 0.46
PIK3R1 P27986 1/20 0.46
PRKDC P78527 1/20 0.46
PIK3C3 Q8NEB9 1/20 0.46
CYP1A2 P05177 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2584987 0.88 SYK (0.48) MAPK1ALOX15METAP1SYKALDH1A1
SCHEMBL14900561 0.86 SYK (0.53) MAPK1ALOX15METAP1AHRSYK
SCHEMBL14902606 0.85 ALOX15 (0.47) MAPK1ALOX15METAP1AHRSYK
SCHEMBL2588826 0.82 PIK3CD (0.57) MAPK1ALOX15METAP1AHRSYK
SCHEMBL14902650 0.82 ALOX15 (0.47) MAPK1ALOX15METAP1SYKALDH1A1
SCHEMBL2589911 0.81 SYK (0.47) MAPK1ALOX15METAP1SYKALDH1A1
SCHEMBL2588987 0.81 METAP1 (0.47) MAPK1ALOX15METAP1AHRSYK
SCHEMBL12385958 0.80 METAP1 (0.47) MAPK1METAP1AHRSYKALDH1A1
SCHEMBL14902607 0.79 MEN1 (0.45) SYKNPC1MAPTRAB9ATSHR
SCHEMBL1858428 0.78 SYK (0.56) MAPK1ALOX15METAP1AHRSYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130109688-A1 Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease KARUS THERAPEUTICS LIMITED (UK) 2013-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109688-A1 Naphthridine derivatives as PI3K inhibitors for the treatment of cancer and immune-inflammatory disease PIK3R5, PIK3CA, NFKBIA MAPK1 63/4885ALOX15 2354/4885METAP1 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.